Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
SA-CME credits are available for this article here. Among the many types of cardiac arrhythmias, ventricular tachycardia (VT) represents a potentially fatal arrhythmia in the setting of abnormal anatomical and physiological pathways of the heart. Specifically, these aberrant pathways result from cardiac injury to the ventricles, either by ischemic causes (postmyocardial infarction) or nonischemic causes (inflammatory or secondary to other systemic pathologies).
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Abstract Introduction A prospective phase I/II trial for electrophysiologic-guided noninvasive cardiac radioablation treatment of ventricular tachycardia (VT) (XXXX) demonstrating efficacy for arrhythmia control has recently been reported. The treatment workflow, report dose-volume metrics, and overall process improvements are described here.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
